| Literature DB >> 25153109 |
Débora Lopes Bunzen1, Nathalia Lins2, Mariana de Carvalho Leal1, Mariana Montenegro de Melo Lira3, Silvio da Silva Caldas Neto1.
Abstract
INTRODUCTION: Several biomaterials can be used in ear surgery to pack the middle ear or support the graft. The absorbable gelatin sponge is the most widely used, but it may produce fibrosis and impair ventilation of the middle ear.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25153109 PMCID: PMC9535480 DOI: 10.1016/j.bjorl.2013.08.001
Source DB: PubMed Journal: Braz J Otorhinolaryngol ISSN: 1808-8686
Fig. 1Wistar rat in lateral decubitus. Surgical incision in the retroauricular region of the left ear. A, anterior; P, posterior.
Fig. 2Exposure of the location of the tympanic bulla, deep to the cervical muscles on the left side of the rat. A, anterior; P, posterior; S, superior; I, inferior.
Fig. 3Materials studied. GF, Gelfoam (absorbable gelatine sponge); BP, sponge of sugarcane biopolymer.
Histological findings in the tympanic bulla of rats after one month of the experiment (T1).
| Histological findings | Muc. Th. | TM. Th. | LMN | PMN | Neoangio | Fibrosis |
|---|---|---|---|---|---|---|
| BP (n = 7) | ||||||
| Absent | 1 (14.28%) | 3 (42.86%) | – | – | 1 (14.28%) | – |
| Light | 3 (42.86%) | 4 (57.14%) | 1 (14.28%) | 1 (14.28%) | 6 (85.71%) | 5 (71.43%) |
| Moderate | – | – | 4 (57.14%) | 3 (42.86%) | – | 2 (28.57%) |
| Intense | 3 (42.86%) | – | 2 (28.57%) | 3 (42.86%) | – | – |
| GF (n = 5) | ||||||
| Absent | 2 (40.0%) | 3 (60.0%) | – | 5 (100%) | – | – |
| Light | 1 (20.0%) | – | 4 (80.0%) | – | 4 (80.0%) | 1 (20.0%) |
| Moderate | 1 (20.0%) | 1 (20.0%) | 1 (20.0%) | – | 1 (20.0%) | 3 (60.0%) |
| Intense | 1 (20.0%) | 1 (20.0%) | – | – | – | 1 (20.0%) |
BP, biopolymer; GF, Gelfoam®; Muc.Th., mucosal thickening; TM.Th., tympanic membrane thickening; LMN, lymphmononuclear infiltrate; PMN, polymorphonuclear infiltrate; Neoangio, neoangiogenesis.
Histological findings in the tympanic bulla of rats after 3 months of the experiment (T2).
| Histological findings | Muc. Th. | TM. Th. | LMN | PMN | Neoangio | Fibrosis |
|---|---|---|---|---|---|---|
| BP (n = 15) | ||||||
| Absent | 1 (6.66%) | 8 (53.33%) | – | – | 5 (33.33%) | 1 (6.66%) |
| Light | 5 (33.33%) | 5 (33.33%) | – | 1 (6.66%) | 8 (53.33%) | 8 (53.33%) |
| Moderate | 4 (26.66%) | 1 (6.66%) | 12 (80.0%) | 6 (40.0%) | 2 (13.33%) | 5 (33.33%) |
| Intense | 5 (33.33%) | 1 (6.66%) | 3 (20.0%) | 8 (53.33%) | – | 1 (6.66%) |
| GF (n = 11) | ||||||
| Absent | 1 (9.09%) | 5 (45.45%) | – | 9 (81.81%) | – | – |
| Light | 1 (9.09%) | 3 (27.27%) | 7 (63.63%) | 1 (9.09%) | 3 (27.27%) | 4 (36.36%) |
| Moderate | 3 (27.27%) | 3 (27.27%) | 4 (36.36%) | – | 7 (63.63%) | 3 (27.27%) |
| Intense | 6 (54.54%) | – | – | 1 (9.09%) | 1 (9.09%) | 4 (36.36%) |
BP, biopolymer; GF, Gelfoam®; Muc.Th., mucosal thickening; TM.Th., tympanic membrane thickening; LMN, lymphmononuclear infiltrate; PMN, polymorphonuclear infiltrate; Neoangio, neoangiogenesis.
Comparison between groups of biomaterials in relation to histological findings in the tympanic bulla of rats after 1 month of experiment (T1).
| Histological findings | Group–T1 | P value | |
|---|---|---|---|
| BP (n = 7) | GF (n = 5) | ||
| Muc. Th. | |||
| Absent/Light | 4 (57.1%) | 3 (60.0%) | > 0.999. |
| Moderate/Severe | 3 (42.9%) | 2 (40.0%) | |
| TM. Th. | |||
| Absent/Light | 7(100%) | 3 (60.0%) | 0.152. |
| Moderate/Severe | 0(0%) | 2 (40.0%) | |
| LMN | |||
| Absent/Light | 1(14.3%) | 4 (80.0%) | 0.062. |
| Moderate/Severe | 6 (85.7%) | 1 (20.0%) | |
| PMN | |||
| Absent/Light | 1(14.3%) | 5 (100%) | 0.015 |
| Moderate/Severe | 6 (85.7%) | 0 (0%) | |
| Neoangio | |||
| Absent/Light | 7(100%) | 4 (80.0%) | 0.417. |
| Moderate/Severe | 0 (0%) | 1 (20.0%) | |
| Fibrosis | |||
| Absent/Light | 5 (71.4%) | 1 (20.0%) | 0.234. |
| Moderate/Severe | 2(28.6%) | 4 (80.0%) | |
Statistically significant (p < 0.05).
Comparison between groups of biomaterials in relation to histological findings in the tympanic bulla of rats after 3 months of experiment (T2).
| Histological findings | Group–T2 | P value | |
|---|---|---|---|
| BP (n = 15) | GF (n = 11) | ||
| Muc. Th. | |||
| Absent/Light | 6 (40.0%) | 2 (18.2%) | 0.234. |
| Moderate/Severe | 9 (60.0%) | 9 (81.8%) | |
| TM. Th. | |||
| Absent/Light | 13 (86.7%) | 8 (72.7%) | 0.620. |
| Moderate/Severe | 2 (13.3%) | 3 (27.3%) | |
| LMN | |||
| Absent/Light | 0 (0%) | 7 (63.6%) | 0.001 |
| Moderate/Severe | 15 (100%) | 4 (36.4%) | |
| PMN | |||
| Absent/Light | 1 (6.7%) | 10 (90.9%) | 0.001 |
| Moderate/Severe | 14 (93.3%) | 1 (9.1%) | |
| Neoangio | |||
| Absent/Light | 13 (86.7%) | 3 (27.3%) | 0.004 |
| Moderate/Severe | 2 (13.3%) | 8 (72.7%) | |
| Fibrosis | |||
| Absent/Light | 9 (60.0%) | 4 (36.4%) | 0.234. |
| Moderate/Severe | 6 (40.0%) | 7 (63.6%) | |
Statistically significant (p < 0.05).